Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.

Saved in:
Bibliographic Details
Title: Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Authors: Raychaudhuri R; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Tuchayi AM; Department of Radiology and Biomedical Imaging, University of California-San Francisco San Francisco CA USA., Low SK; Medical College of Wisconsin Milwaukee WI USA., Arafa AT; University of Minnesota, Masonic Cancer Center Minneapolis MN USA., Graham LS; University of Colorado Medical Center Aurora CO USA., Gulati R; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington Seattle WA USA., Montgomery RB; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Haffner MC; Department of Laboratory Medicine and Pathology, University of Washington Seattle WA USA; Division of Human Oncology, Fred Hutchinson Cancer Center Seattle WA USA., Nelson PS; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Yu EY; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Hawley JE; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Cheng HH; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA., Mo G; Division of Hematology and Oncology, University of Washington Seattle WA USA., Chen DL; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA; Department of Radiology, University of Washington Seattle WA USA., Antonarakis ES; University of Minnesota, Masonic Cancer Center Minneapolis MN USA., Kilari D; Medical College of Wisconsin Milwaukee WI USA., Hope TA; Department of Radiology and Biomedical Imaging, University of California-San Francisco San Francisco CA USA., Iravani A; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA; Department of Radiology, University of Washington Seattle WA USA., Schweizer MT; Division of Hematology and Oncology, University of Washington Seattle WA USA; Clinical Research Division, Fred Hutchinson Cancer Center Seattle WA USA. Electronic address: schweize@uw.edu.
Source: European urology oncology [Eur Urol Oncol] 2026 Apr; Vol. 9 (2), pp. 430-437. Date of Electronic Publication: 2025 Feb 07.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2588-9311
DOI:10.1016/j.euo.2025.01.002